Company: Orthofix International N.V.

OFIX

Stock Code:

Enter Stock Code:

This report provides insider trading pattern and statistics for "Orthofix International N.V. (OFIX)" . Please read important descriptions at the bottom of this report.

Register Free Insider Trade Email Alert for "Orthofix International N.V. (OFIX)" !



 

Analysis & Screening

Chart Screening Tool

  Transaction Date

  Filing Date

Start Date:

Select Start Date

End Date:

Select End Date

Trading History Screening Tool

Transaction Code:

Ownership:

Share Class:

Trade Price From:

to

Transaction History From June 20th, 2017 To July 20th, 2017 (Max 50 Records Displayed)

Filing Date

Trade Date

 

Insider Name

Event Code

Ownership

Trade Information

Holding % Change

Jul 10/17

Jul 03/17

CxO Buy

Elting Kimberley A.

Chief Legal Officer

A

Direct ownership

Acquired 7,050 Performance Share Units

0.00%

Jul 10/17

Jul 03/17

CxO Buy

GOODWIN ROBERT ALLEN II

President Biologics

A

Direct ownership

Acquired 8,516 Stock Option (right to buy)

0.00%

Jul 10/17

Jul 03/17

CxO Buy

GOODWIN ROBERT ALLEN II

President Biologics

A

Direct ownership

Acquired 4,881 Performance Share Units

0.00%

Jul 10/17

Jul 03/17

CxO Buy

FUJIKAWA RAYMOND

President Spine Fixation

A

Direct ownership

Acquired 2,440 Common Stock

6.97%

Jul 10/17

Jul 03/17

CxO Buy

FUJIKAWA RAYMOND

President Spine Fixation

A

Direct ownership

Acquired 8,516 Stock Option (right to buy)

0.00%

Jul 10/17

Jul 03/17

CxO Buy

FUJIKAWA RAYMOND

President Spine Fixation

A

Direct ownership

Acquired 4,881 Performance Share Units

0.00%

Jul 10/17

Jul 03/17

CxO Buy

Finegan Michael

Chief Strategy Officer

A

Direct ownership

Acquired 3,254 Common Stock

7.35%

Jul 10/17

Jul 03/17

CxO Buy

Finegan Michael

Chief Strategy Officer

A

Direct ownership

Acquired 11,355 Stock Option (right to buy)

0.00%

Jul 10/17

Jul 03/17

CxO Buy

Finegan Michael

Chief Strategy Officer

A

Direct ownership

Acquired 6,508 Performance Share Units

0.00%

Jul 10/17

Jul 03/17

CxO Buy

Mason Brad

CEO

A

Direct ownership

Acquired 15,184 Common Stock

8.65%

Jul 10/17

Jul 03/17

CxO Buy

Mason Brad

CEO

A

Direct ownership

Acquired 52,990 Stock Option (right to buy)

0.00%

Jul 10/17

Jul 03/17

CxO Buy

Mason Brad

CEO

A

Direct ownership

Acquired 30,369 Performance Share Units

0.00%

Jul 10/17

Jul 03/17

CxO Buy

DOUG RICE

CFO

A

Direct ownership

Acquired 3,796 Common Stock

7.86%

Jul 10/17

Jul 03/17

CxO Buy

DOUG RICE

CFO

A

Direct ownership

Acquired 13,248 Stock Option (right to buy)

0.00%

Jul 10/17

Jul 03/17

CxO Buy

DOUG RICE

CFO

A

Direct ownership

Acquired 7,592 Performance Share Units

0.00%

Jul 10/17

Jul 03/17

CxO Buy

Elting Kimberley A.

Chief Legal Officer

A

Direct ownership

Acquired 3,525 Common Stock

62.95%

Jul 10/17

Jul 03/17

CxO Buy

Elting Kimberley A.

Chief Legal Officer

A

Direct ownership

Acquired 12,301 Stock Option (right to buy)

0.00%

Jul 10/17

Jul 03/17

CxO Buy

GOODWIN ROBERT ALLEN II

President Biologics

A

Direct ownership

Acquired 2,440 Common Stock

6.99%

Jul 10/17

Jul 03/17

CxO Buy

NIEMANN BRADLEY V.

President Biostim

A

Direct ownership

Acquired 5,965 Performance Share Units

0.00%

Jul 10/17

Jul 03/17

CxO Buy

NIEMANN BRADLEY V.

President Biostim

A

Direct ownership

Acquired 10,409 Stock Option (right to buy)

0.00%

Jul 10/17

Jul 03/17

Company Director Buy

Hinrichs James F.

A

Direct ownership

Acquired 3,579 Common Stock

13.73%

Jul 10/17

Jul 03/17

Company Director Buy

Paolucci Michael E

A

Direct ownership

Acquired 3,579 Common Stock

90.61%

Jul 10/17

Jul 03/17

Company Director Buy

Lukianov Alexis V

A

Direct ownership

Acquired 3,579 Common Stock

0.00%

Jul 10/17

Jul 03/17

Company Director Buy

FAULSTICK LUKE T

A

Direct ownership

Acquired 3,579 Common Stock

39.99%

Jul 10/17

Jul 03/17

Company Director Buy

Sainz Maria

A

Direct ownership

Acquired 3,579 Common Stock

14.18%

Jul 10/17

Jul 03/17

Company Director Buy

MATRICARIA RONALD A

A

Direct ownership

Acquired 6,508 Common Stock

7.76%

Jul 10/17

Jul 03/17

Company Director Buy

MARKS LILLY

A

Direct ownership

Acquired 3,579 Common Stock

34.25%

Jul 10/17

Jul 03/17

CxO Buy

Bianchi Davide

President Extremity Fixation

A

Direct ownership

Acquired 2,983 Common Stock

5.27%

Jul 10/17

Jul 03/17

CxO Buy

Bianchi Davide

President Extremity Fixation

A

Direct ownership

Acquired 10,409 Stock Option (right to buy)

0.00%

Jul 10/17

Jul 03/17

CxO Buy

Bianchi Davide

President Extremity Fixation

A

Direct ownership

Acquired 5,965 Performance Share Units

0.00%

Jul 10/17

Jul 03/17

CxO Buy

NIEMANN BRADLEY V.

President Biostim

A

Direct ownership

Acquired 2,983 Common Stock

6.76%

Jun 27/17

Jun 26/17

CxO Sell

Finegan Michael

Chief Strategy Officer

F

Direct ownership

Disposed -21,961 Common Stock at $46.32

-32.50%

Jun 27/17

Jun 26/17

CxO Sell

Finegan Michael

Chief Strategy Officer

M

Direct ownership

Disposed -22,300 Stock Option (right to buy)

-100.00%

Jun 27/17

Jun 26/17

CxO Buy

Mason Brad

CEO

M

Direct ownership

Acquired 6,667 Common Stock at $44.97

3.69%

Jun 27/17

Jun 26/17

CxO Sell

Mason Brad

CEO

F

Direct ownership

Disposed -6,555 Common Stock at $46.32

-3.50%

Jun 27/17

Jun 26/17

CxO Sell

Mason Brad

CEO

M

Direct ownership

Disposed -6,667 Stock Option (right to buy)

-100.00%

Jun 27/17

Jun 26/17

CxO Buy

Finegan Michael

Chief Strategy Officer

M

Direct ownership

Acquired 22,300 Common Stock at $44.97

49.25%

Company: Orthofix International N.V.

OFIX

Stock Code:

Chart and trading summary tables represent transactions by company directors, chief executives(CEO, CFO, and senior company officers), corporate substantial shareholders, director's/executive's interest in affiliates of listed corporates, and individual substantial shareholders. Data on this page include all "Orthofix International N.V. (OFIX)" securities traded or transferred within the specified date range defined in stock screening and analysis panel beside the chart. (Note that, not all corporate insiders will record their trading price or number of shares bought/sold in their filings. The missing data are not included in the trading summary calculation). Different insider symbols in the price chart represent transaction activities on a particular date (Not Stock Trading Price). Additionally, transaction price in chart and trading summary table are adjusted for foreign currency exchange rate on the best efforts. The trading summary in net stock buying or stock selling totals are done on a best efforts basis. All data presented should be treated as estimates as it is based on insider trade filings which are subject to errors if input mistakes are made by a filers. Mouse over on signals to see the transaction details in the transaction info box. The chart is optimized for IE5 or above.

Disclaimer

InsidersLab.com focuses on tracking and monitoring insider trading activities in the US stocks market. "Insider Trading" means trading activities created by company directors, senior officers, individual substantial shareholders, and institutional shareholders. InsidersLab.com does not represent, warrant, nor endorse the accuracy, reliability, completeness or timeliness of any of the information, content, views, opinions, recommendations or advertisements (collectively, the "Materials") contained on, distributed through, or linked, downloaded or accessed from any of the services contained on the website (the "Service"), nor the quality of any products, information or other materials displayed, purchased, or obtained by you as a result of an advertisement or any other information or offer in or in connection with the Service (the "Products"). InsidersLab.com collects insider trading information from different public sources such as newspapers, financial information websites, and government statistics publications. You hereby acknowledge that any reliance upon any Materials shall be at your sole risk. In particular, none of the Materials is provided on the InsidersLab.com website or emails with a view to inviting, inducing or encouraging any person to make any kind of investment decision. Securities or other investments referred to in the Materials may not be suitable for you and you should not make any kind of investment decision in relation to them without first obtaining independent investment advice from a person authorized to give it.